Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor ACE2 and TMPRSS2 in Inflammatory Bowel DiseaseShow others and affiliations
2020 (English)In: Gastroenterology, ISSN 0016-5085, E-ISSN 1528-0012, Vol. 159, no 3, p. 1151-1154Article in journal, Editorial material (Other academic) Published
Abstract [en]
Although the respiratory tract is implicated as the primary portal of entry of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), gastrointestinal involvement is well-reported, associated with nausea, vomiting, diarrhea, and highly persistent viral particle shedding in feces.(1,2)
There is critical need to establish factors determining susceptibility to Coronavirus Disease 2019 (COVID-19) in patients with inflammatory bowel disease (IBD). Age, comorbidity, disease activity, and exposure to immunomodulatory and biological therapies provide the basis for new guidelines for risk stratification and shielding.(3)
We hypothesize that expression levels of the SARS-CoV-2 spike protein receptor, angiotensin-converting enzyme 2 (ACE2),(4) may also determine susceptibility to SARS-CoV-2-inflicted damage. Transmembrane serine protease 2 (TMPRSS2) primes the viral spike protein,(5) allowing for the potent binding of ACE2. Both are known to be highly expressed in healthy ileal epithelium, with lower levels in epithelial cells in the colon. We report dysregulated mucosal ACE2 and TMPRSS2 expression in the colon and ileum in IBD, and identify the critical determinants of altered expression.
Place, publisher, year, edition, pages
American Gastroenterology Association Institute , 2020. Vol. 159, no 3, p. 1151-1154
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-86452DOI: 10.1053/j.gastro.2020.05.030ISI: 000573218700013PubMedID: 32413354Scopus ID: 2-s2.0-85089734670OAI: oai:DiVA.org:oru-86452DiVA, id: diva2:1476596
Note
Funding Agency:
European Union (EU) 2858546
2020-10-152020-10-152020-10-15Bibliographically approved